134P Safety and efficacy of multi-target TKI combined with nivolumab in checkpoint inhibitor-refractory advanced NSCLC patients: A prospective, single arm, two stage study. (December 2022) - Han, B.; Zhang, B.; Zhong, H.; Shi, C.; Gao, Z.; Zhong, R.; Gu, A.; Chu, T.; Wang, H.; Xiong, L.; Zhang, W.; Zhang, X.; et al.